DiosCURE is advancing next-generation best-in-class immunotherapeutics to prevent and treat SARS-CoV-2 in order to combat the ongoing coronavirus pandemic. Due to their small size, our drug candidates can attach to unique surface structures of the SARS-CoV-2 spike protein.
This passive immunization approach will block the virus’ penetration into target cells which inhibits viral spreading and thereby allows the prevention and treatment of SARS-CoV-2 infections.
We build on a strong scientific foundation of a collaborative effort by the Institute of Innate Immunity of the University Hospital Bonn, The Scripps Research Institute San Diego and the Karolinska Institutet Stockholm. The discovery of our lead candidates was published in the journal Science.
We are a team of professionals with strong expertise in infectious diseases, structural
biology and immunology, as well as rich experience in drug development, clinical trial
execution, business development and start-up management.
With this team and the support of our strong partnerships, we have established a solid foundation to accelerate the development of our unique product candidates.
Tom Schorling, JD
Chief Executive Officer
Dr. Tom Oliver Schorling was for many years a partner at international law firms such as White & Case and Weil, Gotshal & Manges, where he conceived, structured and implemented numerous deals in the billion euro bracket. Tom is one of Germany’s most renowned attorneys and a member of several supervisory boards. In addition, he currently holds senior advisory and investment roles in various tech companies.
Mathias Knecht, MD
Chief Development Officer
Dr. Mathias Knecht brings over two decades of pharmaceutical and biotechnology
experience to DiosCURE. He joined the Company from Allecra Therapeutics, where
he was Chief Development Officer and Managing Director and was responsible for
Allecra’s preclinical and clinical development including the successful execution of
the global pivotal Phase III study for cefepime/enmetazobactam combination in
patients with gram-negative complicated urinary tract infections. Before Allecra,
Mathias held various senior medical, regulatory and development management
positions at Boehringer Ingelheim’s locations in Japan, Canada and Germany. Prior to that, he worked as a physician in Germany. Mathias is a board-certified internal medicine and cardiology physician.
Eicke Latz, MD, PhD
Board member and Scientific Co-founder
Prof. Eicke Latz is the founder and director of the Institute of Innate Immunity at the
University of Bonn, where he directs an international group of scientists. He is also
Adjunct Professor at the Centre for Molecular Inflammation Research at the Norwegian Technical University in Trondheim and heads a research group at the German Center for Neurodegenerative Diseases (DZNE) in Bonn. His research focuses on identifying the most proximal mechanisms of innate immune activation in chronic inflammatory diseases. Eicke is co-founder of several biotech companies, including IFM Therapeutics in Boston, a company developing small molecule
modulators of innate immune pathways. He was awarded the 2018 Gottfried Wilhelm
Leibniz Prize from the German Research Foundation (DFG), also known as the "German Nobel Prize.” Eicke is listed in the World’s Most Influential Minds by Thompson Reuters and is a highly cited scientist in immunology yearly since 2014.
Florian Schmidt, PhD
Dr. Florian Schmidt is an Emmy Noether group leader at the Institute of Innate
Immunity at the University of Bonn. His research focus on the cell biology of innate
immune responses against viruses. To achieve unprecedented molecular insights,
his laboratory generates and applies camelid nanobodies to visualize and perturb
proteins involved in pathogen recognition and inflammatory responses. Together with
Paul-Albert König, he has established the Core Faculty Nanobodies at the University
of Bonn. In 2017, he was awarded the Research Award of the Peter and Traudl
Paul-Albert König, PhD
Dr. Paul-Albert König investigated anti-fungal innate immune signaling pathways
during his postdoctoral fellow at the Technical University Munich. Since 2018, Paul
leads the newly established Core Facility Nanobodies at the University of Bonn to
develop camelid antibody fragments. His research is focused on the development of
innovative selection strategies, new nanobody-based tools and reagents for basic and clinical research, diagnostics or therapy.